Is there an immunologic basis for schizophrenia?

References

• Bruce LC, Peebles AMS. Clinical and experimental observations on catatonia. J. Ment. Sci. 49, 614–628 (1903).
   Google Scholar
• Dameshek W. White blood cells in dementia praecox and dementia paralytica. Arch. Neurol. Psychiat. 24, 855 (1930).
   Google Scholar
• Lehmann-Facius H. Serologisch-analystische Versuche mit Liquores und Seren von Schizophrenen. Allg. Z. Psychiat. 110, 232–243 (1939).
   Google Scholar
• Mueller N, Ackenheil M. Psycho-neuroimmunology, the cytokine network in the CNS and the implication for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiat. 22, 1–31 (1998).
   PubMedGoogle Scholar
• Lindholm E, Elsholm R, Balcinniene J et al. Linkage analysis of a large Swedish kindred provides further support for a susceptibility locus for schizophrenia on chromosome 6p23. Am. J. Med. Genet. 88, 369–377 (1999).
   PubMedGoogle Scholar
• Schwab SG, Albus M, Hallmayer J et al. Evaluation of a susceptibility gene for schizophrenia in chromosome 6p by multipoint affected sib-pair linkage analysis. Nature Genet. 11, 325–327 (1995).
   PubMed Web of Science ®Google Scholar
• Wright P, Sham PC, Gilvarry CM et al. Autoimmune diseases in the pedigrees of schizophrenic and control subjects. Schizophr. Res. 20, 261–267 (1996).
   PubMed Web of Science ®Google Scholar
• Badenhoop K, Tonjes RR, Row H et al. Endogenous retroviral long-terminal repeats of the HLA-DQ region are associated with susceptibility to insulin dependent diabetes mellitus. Hum. Immunol. 50, 103–110 (1996).
   PubMedGoogle Scholar
• Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am. J. Psychiatry 161, 1709–1711 (2004).
   PubMed Web of Science ®Google Scholar
• Fatemi SH, Emamian ES, Kist D et al. Defective corticogenesis and reduction in reelin immunoreactivity in cortex and hippocampus of prenatally infected neonatal mice. Mol. Psychiatry 2, 145–154 (1999).
   Google Scholar
• Impagnatiello F, Guidotti AR, Pesold C et al. A decrease in reelin expression on a putative vulnerability factor in schizophrenia. Proc. Natl Acad. Sci. USA 95, 15718–15723 (1998).
   PubMed Web of Science ®Google Scholar
• Moises HW, Ruger R, Reynolds GP, Fleckenstein B. Human cytomegalovirus DNA in the temporal cortex of a schizophrenic patient. Eur. Arch. Psychiatry Neurol. Sci. 238, 110–113 (1988).
   PubMedGoogle Scholar
• Schwartz MJ, Mueller N, Riedel M, Ackenheil M. Markers of cellular and humoral immune activity: a shift in schizophrenia. In: Psychoneuroimmunology, Hypothesis and Current Research. Sperner-Unterweger B, Fleischhakker WW, Kaschka WP (Eds), Adv. Biol. Psychiatry 20, 61–65 Karger, Basel, Switzerland (2001).
   Google Scholar
• Mueller N, Schlesinger BC, Hadjaniu M et al. Cytotoxic γ/δ cells are elevated in unmedicated schizophrenic patients and related to the blood–brain barrier and HLA allele DPA 02011. Schizophr. Res. 12, 69–71 (1998).
   Google Scholar
• Wilke I, Arolt V, Rothermund M et al. Neopterin production in acute schizophrenic patients: an indicator of alterations of cell mediated immunity. Psychiatry Res. 42, 121–128 (1992).
   PubMedGoogle Scholar
• Zorrilla EP, Cannon TD, Gur RE, Kessler J. Leukocytes and organ non-specific autoantibodies in schizophrenics and their siblings: markers of vulnerability of disease? Biol. Psychiatry 40, 825–833 (1996).
   PubMed Web of Science ®Google Scholar
• Rudolf S, Schlenke P, Broocks A et al. Search for atypical lymphocytes in schizophrenia. World J. Biol. Psychiatry 1, 33–37 (2004).
   Google Scholar
• Nikkila HV, Muller K, Ahokas A et al. Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am. J. Psychiatry 156, 1725–1729 (1999).
   PubMedGoogle Scholar
• Plata-Salaman CR. Immunoregulation in the central nervous system. Neuroscience Biobehav. Rev. 15, 185–215 (1991).
   PubMed Web of Science ®Google Scholar
• Frei K, Malipiero UV, Leist TP et al. On the cellular source and function of IL-6 produced in the CNS in viral diseases. Eur. J. Immunol. 19, 689–694 (1989).
   PubMed Web of Science ®Google Scholar
• Spangelobl, Judd AM, Isakson PC, Macleod RM. IL-6 stimulates anterior pituitary hormone release in vitro. Endocrinology 125, 575–577 (1989).
   PubMedGoogle Scholar
• Hama T, Kushima Y, Miyamoto M et al. IL-6 improves survival of mesencephalic catecholaminergic and septal cholinergic neurons from post natal 2 week old rat cultures. Neuroscience 40, 445–452 (1991).
   PubMed Web of Science ®Google Scholar
• Zalcman S, Green-Johnson JM, Murray L et al. Cytokine specific central monoamine alterations induced by IL-1, IL-2 and IL-6. Brain Res. 643, 40–49 (1994).
   PubMed Web of Science ®Google Scholar
• Maes M, Bosman E, Calabrese J, Smith R, Meltzer H. IL-2 and IL-6 in schizophrenia and mania; effects of neuroleptics and mood stabilisers. J. Psychiatr. Res. 29, 141–152 (1995).
   PubMed Web of Science ®Google Scholar
• Ganguli R, Yang Z, Shurin G et al. Serum IL-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 51, 1–10 (1994).
   PubMed Web of Science ®Google Scholar
• Frommberger UH, Bauer J, Haselbauer P et al. IL-6 plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci. 247, 228–232 (1997).
   PubMed Web of Science ®Google Scholar
• van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK. Methodological concerns in the study of the immune system in schizophrenia. In: Psychiatry, Psychoimmunology and Viruses. Mueller N (Ed.), Springer Verlag, Vienna, Austria, 63–69 (1999).
   Google Scholar
• Ganguli R, Yang Z, Shurin G et al. Serum IL-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 51, 1–10 (1994).
   PubMed Web of Science ®Google Scholar
• Lin A, Kenis G, Bignotti S et al. The inflammatory response system in treatment resistant schizophrenia: increased serum IL-6. Schizophr. Res. 32, 9–15 (1998).
   PubMed Web of Science ®Google Scholar
• Mueller N, Dobmeier P, Empel M et al. Soluble IL-6 receptor in serum and cerebrospinal fluid of paranoid schizophrenic patients. Eur. Psychiat. 12, 294–299 (1997).
   PubMedGoogle Scholar
• Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29, 1004–1011 (2004).
   PubMed Web of Science ®Google Scholar
• Heath RG, Krupp I. Schizophrenia as an immunological disorder. Arch. Gen. Psychiatry 16, 1–33 (1967).
   PubMed Web of Science ®Google Scholar
• Koerschenhausen D, Hampel H, Ackenheil M et al. Fibrin degredation products in post mortem brain tissue: a possible marker of underlying inflammatory process. Schizophr. Res. 19, 103–109 (1996).
   PubMedGoogle Scholar
• Radewicz K, Garey LJ, Gentleman SM, Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex in chronic schizophrenia. J. Neuropathol. Exp. Neurol. 59, 137–150 (2000).
   PubMedGoogle Scholar
• Wong M-L, Licinio J. Localization of IL-1 receptor mRNA in rat brain. Neuroimmunomodulation 1, 110–115 (1994).
   PubMedGoogle Scholar
• Akiyama K. Serum levels of sIL-2R, IL-6 and IL-1RA in schizophrenics before and during neuroleptic administration. Schizophr. Res. 37, 97–106 (1999).
   PubMedGoogle Scholar
• Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale W. IL-1 stimulates the secretion of hypothalamic CRF. Science 238, 522–524 (1987).
   PubMed Web of Science ®Google Scholar
• Vereker E, O’Donnell E, Lynch MA. The inhibitory effect of IL-1 β on long-term potentiation is coupled with increased activity of stress-activated protein kinases. J. Neurosci. 20, 6811–6819 (2000).
   PubMed Web of Science ®Google Scholar
• Barak V, Barak Y, Levine J, Nisman B, Roisman I. Changes in interleukin-1 β and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J. Basic Clin. Physiol. Pharmacol. 6, 61–69 (1995).
   PubMedGoogle Scholar
• Ganguli R, Rabin BS. Decreased IL-2 production in schizophrenic patients. Biol. Psychiatry 26(4), 427–430 (1989).
   PubMed Web of Science ®Google Scholar
• Shintani F, Shigenobu K, Marno N. Serum IL-6 in schizophrenic patients. Life Sci. 49, 661–664 (1991).
   PubMed Web of Science ®Google Scholar
• Theodoropoulou ST, Spanako G, Baxevanis CN et al. Cytokine levels, autologous mixed lymphocyte reaction and surface marker serum analysis in never medicated and chronically medicated schizophrenic patients. Schizophr. Res. 47, 13–25 (2001).
   PubMed Web of Science ®Google Scholar
• Cazzullo CL, Sacchetti E, Galluzzo A et al. Cytokine profiles in drug naive schizophrenic patients. Schizophr. Res. 47, 293–298 (2001).
   PubMedGoogle Scholar
• Zang XY, Zhou DF, Zhang PY et al. Elevated IL-2, IL-6 and IL-8 serum levels in neuroleptic free schizophrenics: association with psychopathology. Schizophr. Res. 57, 247–258 (2002).
   PubMedGoogle Scholar
• Maes M, Chiavetto LB, Bignotti S et al. Increased serum IL-8 and IL-10 in schizophrenics resistant to neuroleptics and the stimulant effects of clozapine on serum leukaemia inhibitory factor receptor. Schizophr. Res. 54, 281–291 (2001).
   Google Scholar
• Cazzullo CL, Sacchetti E, Galluzzo A et al. Cytokine profiles in schizophrenic patients treated with risperidone: a 3 month follow-up study. Prog. Neuropsychopharmacol. Biol. Psychiatry 26, 33–39 (2002).
   PubMed Web of Science ®Google Scholar
• Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H. Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology 37, 186–193 (1998).
   PubMedGoogle Scholar
• Arolt V, Rothermundt M, Wandinger KP, Kirchner H. Decreased in vitro production of interferon-γ and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol. Psychiatry 5, 150–158 (2000).
   PubMed Web of Science ®Google Scholar
• Rothermundt M, Arolt V, Leadbeater J et al. Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport 11, 3385–3388 (2000).
   PubMedGoogle Scholar
• Haack M, Hinze-Selch D, Fenzel T et al. Plasma levels of cytokine receptors in psychiatric patients upon hospital administration: effects of confounding factors in diagnosis. J. Psychiatr. Res. 33, 407–418 (1999).
   PubMed Web of Science ®Google Scholar
• Baldolato R, Oppenheim JJ. Role of cytokines, acute phase proteins and chemokines in the progression of rheumatoid arthritis. Arthritis Rheum. 26, 526–538 (1996).
   Google Scholar
• Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17, 138–146 (1996).
   PubMedGoogle Scholar
• Cazzullo CL, Scarone S, Grassi B et al. Cytokine production in chronic schizophrenic patients with and without paranoid behaviour. Prog. Neuropsychopharmacol. Biol. Psychiat. 22, 947–957 (1998).
   PubMed Web of Science ®Google Scholar
• Mittleman BB, Castellanos FX, Jacobson LK et al. CSF cytokines in pediatric neuropsychiatric disease. J. Immunol. 139, 2994–2999 (1997).
   Google Scholar
• Ramchaud R, Wei J, Ramchaud CN, Hemmings GP. Increased serum IgE in schizophrenic patients who respond poorly to neuroleptic treatment. Life Sci. 54, 1579–1584 (1994).
   PubMedGoogle Scholar
• Cazzullo CL, Saresella M, Roda K et al. Increased levels of CD8+ and CD4+ 45RA+ lymphocytes in schizophrenic patients. Schizophr. Res. 31, 49–55 (1998).
   PubMed Web of Science ®Google Scholar
• Schwarz MJ, Mueller N, Riedel M, Ackenheil M. Markers of cellular and humoral immune activity: Th2 shift in schizophrenia? In: Psychoneuroimmunology, Hypothesis and Current Research. Sperner-Unterweger B, Fleischakker WW, Kaschka WP (Eds), Advances Biol. Psychiatr. Karger, Basel, Switzerland 61–65 (2001).
   Google Scholar
• Villemain F, Chatenard L, Galinowski A et al. Aberrant T-cell mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am. J. Psychiatry 146, 609–616 (1989).
   PubMed Web of Science ®Google Scholar
• Ganguli R, Brar JS, Chengappa KR et al. Mitogen stimulated IL-2 production in never medicated first episode schizophrenics: the influence of age of onset and negative symptoms. Arch. Gen. Psychiatry 52, 878 (1995).
   PubMedGoogle Scholar
• Moises HW, Schindler L, Leroux M, Kirchner H. Decreased production of interferon α and interferon γ in leucocyte cultures of schizophrenic patients. Acta Psychiatr. Scand. 72, 45–50 (1985).
   PubMedGoogle Scholar
• Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. The LFA-1 ligand ICAM provides an important co-stimulatory signal for T-cell receptor mediated activation of resting T-cells. J. Immunol. 144, 4579–4586 (1990).
   PubMed Web of Science ®Google Scholar
• Mueller N, Riedel M, Ackenheil M, Schwarz MJ. Immune function in schizophrenia: the role of disease and antipsychotic medication. In: Psychoneuroimmunology, Hypothesis and Current Research. Sperner-Unterweger B, Fleischhakker WW, Kashka WP (Eds). Advan. Biol. Psychiatry 20, 75–86 Karger, Basel, Switzerland (2001).
   Google Scholar
• Vinogradov S, Gottesma II, Moises HW, Nicol S. Negative association between schizophrenia and rheumatoid arthritis. Schizophr. Bull. 17, 669–678 (1991).
   PubMedGoogle Scholar
• Fuller-Torrey E, Yolken RN. The schizophrenia–rheumatoid arthritis connection: infection, immune or both? Brain Behav. Immun. 15, 401–410 (2001).
   PubMedGoogle Scholar
• Molholm HB. Hyposensitivity to foreign proteins in schizophrenic patients. Psychiat. Q. 16, 565–571 (1942).
   Google Scholar
• Ozek M, Toreci K, Akkok I, Guevener Z. The influence of treatment with neuroleptics upon the antibody formation. Psychopharmacology 21, 401–412 (1971).
   PubMedGoogle Scholar
• Munn NA. Microglia dysfunction in schizophrenia: an integrative theory. Med. Hypotheses 54, 198–202 (2000).
   PubMed Web of Science ®Google Scholar
• Radewicz K, Garey LJ, Gentleman SM, Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 59, 137–150 (2000).
   PubMedGoogle Scholar
• Gehrmann J, Matsumoto Y, Kreutzberg GW. Microglia: intrinsic immunoeffector cell of the brain. Brain Res. Rev. 20, 269–287 (1995).
   PubMed Web of Science ®Google Scholar
• Wilke I, Arolt V, Rothermund M et al. Neopterin production in acute schizophrenic patients: an indicator of alterations in cell mediated immunity. Psychiatry Res. 42, 121–128 (1996).
   Google Scholar
• Mueller N, Empel M, Riedel M, Schwarz MJ, Ackenheil M. Neuroleptic treatment increases sIL-2 R and decreases IL-6R in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 247, 308–313 (1997).
   PubMedGoogle Scholar
• Pollmacher T, Hinze-Selch D, Mullington J, Holsboer F. Clozapine induced increase in plasma sIL2R. Arch. Gen. Psychiatry 52, 877–878 (1995).
   PubMed Web of Science ®Google Scholar
• Maes M, Meltzer H, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 89, 346–356 (1994).
   PubMed Web of Science ®Google Scholar
• Tanaka KF, Shintani F, Fugii Y et al. Serum IL-18 levels are elevated in schizophrenia. Psychiatry Res. 96, 75–80 (2000).
   PubMed Web of Science ®Google Scholar
• Schwarz MJ, Riedel M, Ackenheil M, Mueller N. Soluble intracellular adhesion molecule-1 levels are decreased in unmedicated and medicated schizophrenic brains. Biol. Psychiatry 47, 29–33 (1999).
   Google Scholar
• Rudolf S, Peters M, Rothremundt M, Arolt V, Kirchner H. The influence of typical and atypical neuroleptic drugs on the production of IL-2 and INF γ in vitro. Neuropsychobiology 46, 180–185 (2002).
   PubMed Web of Science ®Google Scholar
• Prud’homme GJ, Piccirillo CA. The inhibitory effect of transforming growth factor β 1 on autoimmune disease. J. Autoimmun. 14, 23–42 (2000).
   PubMed Web of Science ®Google Scholar
• Vawter MP, Dillon-Carter O, Tourtellotte WW et al. TGF β 1 and TGF β 2 concentrations are elevated in Parkinson’s disease in ventricular cerebrospinal fluid. Exp. Neurol. 142, 313–322 (1996).
   PubMed Web of Science ®Google Scholar
• Kim Y-K, Myint A-M, Lee B-H et al. Th1, Th2 and Th3 cytokine alterations in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry (2005) (In Press).
   Google Scholar
• Gallien M, Schnetzler JP, Morin J. Antinuclear antibodies and lupus cells in 600 hospitalized phenothiazine treated patients. Ann. Med. Psychol. Med. 1, 237–248 (1977).
   PubMedGoogle Scholar
• Zarrabi MH, Zucker S, Miller F et al. Immunologic and coagulation disorders in chlorpromazine treated patients. Ann. Intern. Med. 91, 194–199 (1979).
   PubMed Web of Science ®Google Scholar
• Ganguli R, Rabin BS, Kelly RH, Lyte M, Ragu U. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann. NY Acad. Sci. 496, 676–685 (1987).
   PubMed Web of Science ®Google Scholar
• Mueller N, Riedel M, Schwarz M, Grueber R, Ackenheil M. Immunomodulatory effects of neuroleptics on the cytokine and cellular immune system in schizophrenia. In: Current Update in Psychoimmunology. Wieselmann G (Ed.), Springer Verlag, Vienna, Austria, 57–67 (1997).
   Google Scholar
• Mueller N, Ackenheil M. Immunglobulin and albumin content of CSF in schizophrenic patients: the relationship to negative symptomatology. Schizophr. Res. 14, 223–228 (1995).
   PubMedGoogle Scholar
• Schwarz MJ, Riedal M, Grueber R, Ackenheil M, Mueller N. Antibodies in heat shock proteins in schizophrenic patients: implications for disease mechanism. Am. J. Psychiatry 156, 1103–1104 (1999).
   PubMed Web of Science ®Google Scholar
• Schwarz MJ, Riedel M, Grueber R, Mueller N, Ackenheil M. Autoantibodies against 60 kDa heat shock proteins in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 248, 282–288 (1998).
   PubMed Web of Science ®Google Scholar
• Spivak B, Radwan M, Bartur P, Mester R, Weizman A. Antinuclear antibodies in chronic schizophrenia. Acta Psychiatr. Scand. 92, 266–269 (1995).
   PubMedGoogle Scholar
• Atkinson MA. Molecular mimicry and the pathogenesis of insulin independent diabetes mellitus: still just an alternative hypothesis? Ann. Med. 29, 393–399 (1997).
   PubMed Web of Science ®Google Scholar
• Leiter EH. Genetics and immunogenetics of NOD mice and related strains. In: Research Applications in Diabetes, AIDS, Cancer and Other Diseases. Leiter EH, Atkinson MA (Eds), RG Landes, TX, USA, 37–70 (1998).
   Google Scholar
• Menninger KA. Influenza and schizophrenia: an analysis of post influenza dementia praecox as of 1918 and 5 years later. Am. J. Psychiatry 5, 469–529 (1926).
   Google Scholar
• Menninger KA. The schizophrenia syndrome as a product of acute infectious disease. Arch. Neurol. Psychiatr. 20, 464–481 (1928).
   Google Scholar
• Menninger KA. Psychosis associated with influenza. J. Am. Med. Assoc. 72, 235–241 (1919).
   Google Scholar
• Koerschenhausen D, Hampel H, Ackenheil M. Fibrin degredation products in post mortem brain tissue of schizophrenics: a possible marker for an underlying inflammatory process. Schizophr. Res. 19, 103–109 (1996).
   PubMedGoogle Scholar
• Wildenauer D, Hoechtlen W. Liquorproteine bei psychiatrischen Erkranungen. In: Psychoimmunologie. Kaschka WP, Aschauer NH (Eds), Thieme, Stuttgart, Germany, 75–81 (1990).
   Google Scholar
• Zoroglu SS, Herken H, Yurekli M et al. The posssible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J. Psychiatr. Res. 36, 309–315 (2002).
   PubMed Web of Science ®Google Scholar
• Mueller N, Strassnig M, Schwarz MJ, Ulmschneider M, Riedel M. COX-2 inhibitors as adjuctive therapy in schizophrenia. Expert Opin. Invest. Drugs 13, 1033–1044 (2004).
   PubMed Web of Science ®Google Scholar
• Hilkens CM, Snijders A, Snijdewint FG. Modulation of T-cell cytokine secretion by accessory cell derived products. Eur. Respir. J. 22, S90–S94 (1996).
   Google Scholar
• Hinson RM, Williams JA, Shacter E. Elevated IL-6 induced by PGE2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc. Natl Acad. Sci. USA 93, 4885–4890 (1996).
   PubMed Web of Science ®Google Scholar
• Harris SG, Padilla J, Koumash L. Prostaglandins as modulators of immunity. Trends Immunol. 23, 144–150 (2002).
   PubMed Web of Science ®Google Scholar
• Mueller N, Riedel M, Scheppach E et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry 159, 1029–1034 (2002).
   PubMedGoogle Scholar
• Peet M. New strategies for the treatment of schizophrenia: omega 3 polyunsaturated fatty acids. In: Phospholipid Spectrum Disorder. Peet M, Glen I, Horrobin D (Eds), Marius Press, Lancaster, UK, 189–194 (1999).
   Google Scholar